FDA Approves Gilead’s COVID-19 Drug for Young Children


(Reuters) – The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc’s drug remdesivir.

The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.

The Food and Drug Administration’s (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.

The approval is applicable to children who are hospitalized, or have mild-to-moderate disease and are at high risk of severe COVID-19.

Articles You May Like

No prison time for Tennessee nurse convicted of fatal drug error
Severe COVID Is Equivalent To 20 Years Of Aging – New Study
Grace Victory: The power of vulnerability
Blood adenosine levels positively correlate to the white matter lesions in very low birth weight premature infants
More than half of early Covid patients at one hospital had symptoms two years later

Leave a Reply

Your email address will not be published.